«Primary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptor». Journal of Neurochemistry63 (2): 465-9. August 1994. PMID8035173. doi:10.1046/j.1471-4159.1994.63020465.x.
«Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone». Journal of Neural Transmission105 (4-5): 365-96. 1998. PMID9720968. doi:10.1007/s007020050064.
«The human polyomavirus, JCV, uses serotonin receptors to infect cells». Science306 (5700): 1380-3. November 2004. PMID15550673. doi:10.1126/science.1103492.
«Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release». Brain Research825 (1–2): 161-71. April 1999. PMID10216183. doi:10.1016/S0006-8993(99)01224-X.
«A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex». Neuroscience105 (2): 379-92. 2001. PMID11672605. doi:10.1016/S0306-4522(01)00199-3.
«The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity». Journal of Neurochemistry95 (6): 1597-607. December 2005. PMID16277612. doi:10.1111/j.1471-4159.2005.03485.x.
«Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex». Cerebral Cortex14 (3): 281-99. March 2004. PMID14754868. doi:10.1093/cercor/bhg128.
«AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes». Progress in Neuro-Psychopharmacology & Biological Psychiatry32 (1): 62-71. January 2008. PMID17728034. doi:10.1016/j.pnpbp.2007.07.009.
«Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors». Neuropsychopharmacology23 (5): 569-76. November 2000. PMID11027922. doi:10.1016/S0893-133X(00)00136-6.
Geurts FJ, De Schutter E, Timmermans JP (June 2002). «Localization of 5-HT2A, 5-HT3, 5-HT5A and 5-HT7 receptor-like immunoreactivity in the rat cerebellum». Journal of Chemical Neuroanatomy24 (1): 65-74. PMID12084412. doi:10.1016/S0891-0618(02)00020-0.
«Serotonin2A receptor-like immunoreactivity in rat cerebellar Purkinje cells». Neuroscience Letters252 (1): 72-4. August 1998. PMID9756362. doi:10.1016/S0304-3940(98)00546-1.
«Expression of serotonin2A receptors in Purkinje cells of the developing rat cerebellum». Neuroscience Research50 (4): 411-7. December 2004. PMID15567478. doi:10.1016/j.neures.2004.08.010.
«Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency». The Journal of Pharmacology and Experimental Therapeutics327 (2): 316-23. November 2008. PMID18708586. doi:10.1124/jpet.108.143461.
«Defective repair of 5-hydroxy-2'-deoxycytidine in Cockayne syndrome cells and its complementation by Escherichia coli formamidopyrimidine DNA glycosylase and endonuclease III». Free Radical Biology & Medicine48 (5): 681-90. March 2010. PMID11923449. doi:10.1016/j.freeradbiomed.2009.12.007.
«Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors». ChemMedChem3 (9): 1299-309. September 2008. PMID18666267. doi:10.1002/cmdc.200800133.
«Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI». Journal of Psychopharmacology21 (5): 477-85. July 2007. PMID17092965. doi:10.1177/0269881106072506.
«Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists». Molecular Pharmacology70 (6): 1956-64. December 2006. PMID17000863. doi:10.1124/mol.106.028720.
«1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists». Journal of Medicinal Chemistry49 (19): 5794-803. September 2006. PMID16970404. doi:10.1021/jm060656o.
«2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists». Bioorganic & Medicinal Chemistry Letters13 (14): 2369-72. July 2003. PMID12824036. doi:10.1016/S0960-894X(03)00403-7.
«Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists». Journal of Medicinal Chemistry44 (6): 1003-10. March 2001. PMID11300881. doi:10.1021/jm000491y.
«Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis». Clinical Neuropharmacology29 (2): 80-6. 2006. PMID16614540. doi:10.1097/00002826-200603000-00005.
«AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist». Journal of Ocular Pharmacology and Therapeutics23 (1): 1-13. February 2007. PMID17341144. doi:10.1089/jop.2006.0093.
«1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity». Journal of Medicinal Chemistry49 (1): 318-28. January 2006. PMID16392816. doi:10.1021/jm050663x.
«2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists». Bioorganic & Medicinal Chemistry Letters18 (6): 2103-8. March 2008. PMID18282705. doi:10.1016/j.bmcl.2008.01.090.
«9-(Aminomethyl)-9,10-dihydroanthracene is a novel and unlikely 5-HT2A receptor antagonist». European Journal of Pharmacology380 (1): R5-7. September 1999. PMID10513561. doi:10.1016/S0014-2999(99)00525-7.
«Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands». Current Topics in Medicinal Chemistry2 (6): 575-98. June 2002. PMID12052195. doi:10.2174/1568026023393741.
«Spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine-a structurally unique tetracyclic 5-HT2A receptor antagonist». European Journal of Pharmacology482 (1-3): 335-7. December 2003. PMID14660041. doi:10.1016/j.ejphar.2003.09.059.
«2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands». Bioorganic & Medicinal Chemistry Letters17 (9): 2643-8. May 2007. PMID17314044. doi:10.1016/j.bmcl.2007.01.098.
«Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist». The Journal of Pharmacology and Experimental Therapeutics317 (2): 910-8. May 2006. PMID16469866. doi:10.1124/jpet.105.097006.
«Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders». Expert Opinion on Pharmacotherapy9 (18): 3251-9. December 2008. PMID19040345. doi:10.1517/14656560802532707.
«Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors». The Journal of Pharmacology and Experimental Therapeutics321 (3): 1054-61. June 2007. PMID17337633. doi:10.1124/jpet.106.117507.
«Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior». Neuron53 (3): 439-52. February 2007. PMID17270739. doi:10.1016/j.neuron.2007.01.008.
«Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells». European Journal of Pharmacology594 (1-3): 32-8. October 2008. PMID18703043. doi:10.1016/j.ejphar.2008.07.040.
«OSIRIS: a tool for retrieving literature about sequence variants». Bioinformatics22 (20): 2567-9. October 2006. PMID16882651. doi:10.1093/bioinformatics/btl421. «Supplementary material to article».
«Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists». Journal of Medicinal Chemistry44 (6): 1003-10. March 2001. PMID11300881. doi:10.1021/jm000491y.
«Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene». Neuropsychobiology49 (1): 38-41. 2004. PMID14730199. doi:10.1159/000075337.
«Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group». Lancet347 (9011): 1294-6. May 1996. PMID8622505. doi:10.1016/s0140-6736(96)90939-3.
«Association study of two polymorphisms of the serotonin-2A receptor gene and suicide attempts». American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 147B (5): 645-9. July 2008. PMID18163387. doi:10.1002/ajmg.b.30642.
«HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies». Current Medicinal Chemistry14 (19): 2053-69. 2007. PMID17691947. doi:10.2174/092986707781368450.
«Genetic evaluation of the serotonergic system in chronic fatigue syndrome». Psychoneuroendocrinology33 (2): 188-97. February 2008. PMID18079067. doi:10.1016/j.psyneuen.2007.11.001.
«[11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography». Life Sciences58 (10): PL 187-92. 1996. PMID8602111. doi:10.1016/0024-3205(96)00013-6.
«Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography». Biological Psychiatry55 (3): 217-24. February 2004. PMID14744461. doi:10.1016/j.biopsych.2003.08.015.
«Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei». The International Journal of Neuropsychopharmacology8 (3): 391-401. September 2005. PMID15801987. doi:10.1017/S1461145705005055.
«Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome». The International Journal of Neuropsychopharmacology10 (2): 245-52. April 2007. PMID16945163. doi:10.1017/S1461145706006559.
«Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging». Psychiatry Research68 (1): 11-22. November 1996. PMID9027929. doi:10.1016/S0925-4927(96)02806-5.
«Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction». Brain Research813 (1): 167-71. November 1998. PMID9824691. doi:10.1016/S0006-8993(98)00909-3.
«A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables». NeuroImage21 (3): 1105-13. March 2004. PMID15006678. doi:10.1016/j.neuroimage.2003.10.046.
«Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder». Biological Psychiatry63 (6): 569-76. March 2008. PMID17884017. doi:10.1016/j.biopsych.2007.07.009.
«Primary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptor». Journal of Neurochemistry63 (2): 465-9. August 1994. PMID8035173. doi:10.1046/j.1471-4159.1994.63020465.x.
«Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone». Journal of Neural Transmission105 (4-5): 365-96. 1998. PMID9720968. doi:10.1007/s007020050064.
«The human polyomavirus, JCV, uses serotonin receptors to infect cells». Science306 (5700): 1380-3. November 2004. PMID15550673. doi:10.1126/science.1103492.
«Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain». Molecular Pharmacology43 (1): 84-9. January 1993. PMID8423772.
«Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists». Brain Research Bulletin56 (5): 441-51. November 2001. PMID11750789.
«Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release». Brain Research825 (1–2): 161-71. April 1999. PMID10216183. doi:10.1016/S0006-8993(99)01224-X.
«A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex». Neuroscience105 (2): 379-92. 2001. PMID11672605. doi:10.1016/S0306-4522(01)00199-3.
«The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity». Journal of Neurochemistry95 (6): 1597-607. December 2005. PMID16277612. doi:10.1111/j.1471-4159.2005.03485.x.
«Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex». Cerebral Cortex14 (3): 281-99. March 2004. PMID14754868. doi:10.1093/cercor/bhg128.
«Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons». The Journal of Neuroscience21 (17): 6502-11. September 2001. PMID11517239.
«AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes». Progress in Neuro-Psychopharmacology & Biological Psychiatry32 (1): 62-71. January 2008. PMID17728034. doi:10.1016/j.pnpbp.2007.07.009.
«Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors». Neuropsychopharmacology23 (5): 569-76. November 2000. PMID11027922. doi:10.1016/S0893-133X(00)00136-6.
Geurts FJ, De Schutter E, Timmermans JP (June 2002). «Localization of 5-HT2A, 5-HT3, 5-HT5A and 5-HT7 receptor-like immunoreactivity in the rat cerebellum». Journal of Chemical Neuroanatomy24 (1): 65-74. PMID12084412. doi:10.1016/S0891-0618(02)00020-0.
«Serotonin2A receptor-like immunoreactivity in rat cerebellar Purkinje cells». Neuroscience Letters252 (1): 72-4. August 1998. PMID9756362. doi:10.1016/S0304-3940(98)00546-1.
«Expression of serotonin2A receptors in Purkinje cells of the developing rat cerebellum». Neuroscience Research50 (4): 411-7. December 2004. PMID15567478. doi:10.1016/j.neures.2004.08.010.
«Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency». The Journal of Pharmacology and Experimental Therapeutics327 (2): 316-23. November 2008. PMID18708586. doi:10.1124/jpet.108.143461.
«5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells». The Journal of Neuroscience21 (10): 3572-9. May 2001. PMID11331386.
«Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI». The Journal of Neuroscience22 (21): 9635-42. November 2002. PMID12417689.
«Defective repair of 5-hydroxy-2'-deoxycytidine in Cockayne syndrome cells and its complementation by Escherichia coli formamidopyrimidine DNA glycosylase and endonuclease III». Free Radical Biology & Medicine48 (5): 681-90. March 2010. PMID11923449. doi:10.1016/j.freeradbiomed.2009.12.007.
«Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors». ChemMedChem3 (9): 1299-309. September 2008. PMID18666267. doi:10.1002/cmdc.200800133.
«Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI». Journal of Psychopharmacology21 (5): 477-85. July 2007. PMID17092965. doi:10.1177/0269881106072506.
«Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists». Molecular Pharmacology70 (6): 1956-64. December 2006. PMID17000863. doi:10.1124/mol.106.028720.
Prabhakaran J, Solingapuram Sai KK, Zanderigo F, Rubin-Falcone H, Jorgensen MJ, Kaplan JR, Tooke KI, Mintz A, Mann JJ, Kumar JS. In vivo evaluation of [18F]FECIMBI-36, an agonist 5-HT2A/2C receptor PET radioligand in nonhuman primate. Bioorg Med Chem Lett. 2017 Jan 1;27(1):21-23. doi: 10.1016/j.bmcl.2016.11.043. PubMed
«1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists». Journal of Medicinal Chemistry49 (19): 5794-803. September 2006. PMID16970404. doi:10.1021/jm060656o.
«2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists». Bioorganic & Medicinal Chemistry Letters13 (14): 2369-72. July 2003. PMID12824036. doi:10.1016/S0960-894X(03)00403-7.
«Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists». Journal of Medicinal Chemistry44 (6): 1003-10. March 2001. PMID11300881. doi:10.1021/jm000491y.
«Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis». Clinical Neuropharmacology29 (2): 80-6. 2006. PMID16614540. doi:10.1097/00002826-200603000-00005.
«AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist». Journal of Ocular Pharmacology and Therapeutics23 (1): 1-13. February 2007. PMID17341144. doi:10.1089/jop.2006.0093.
«1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity». Journal of Medicinal Chemistry49 (1): 318-28. January 2006. PMID16392816. doi:10.1021/jm050663x.
«2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists». Bioorganic & Medicinal Chemistry Letters18 (6): 2103-8. March 2008. PMID18282705. doi:10.1016/j.bmcl.2008.01.090.
«9-(Aminomethyl)-9,10-dihydroanthracene is a novel and unlikely 5-HT2A receptor antagonist». European Journal of Pharmacology380 (1): R5-7. September 1999. PMID10513561. doi:10.1016/S0014-2999(99)00525-7.
«Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands». Current Topics in Medicinal Chemistry2 (6): 575-98. June 2002. PMID12052195. doi:10.2174/1568026023393741.
«Spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine-a structurally unique tetracyclic 5-HT2A receptor antagonist». European Journal of Pharmacology482 (1-3): 335-7. December 2003. PMID14660041. doi:10.1016/j.ejphar.2003.09.059.
«2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands». Bioorganic & Medicinal Chemistry Letters17 (9): 2643-8. May 2007. PMID17314044. doi:10.1016/j.bmcl.2007.01.098.
«5-hydroxytryptamine2A receptor inverse agonists as antipsychotics». The Journal of Pharmacology and Experimental Therapeutics299 (1): 268-76. October 2001. PMID11561089.
«Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist». The Journal of Pharmacology and Experimental Therapeutics317 (2): 910-8. May 2006. PMID16469866. doi:10.1124/jpet.105.097006.
«Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders». Expert Opinion on Pharmacotherapy9 (18): 3251-9. December 2008. PMID19040345. doi:10.1517/14656560802532707.
«Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors». The Journal of Pharmacology and Experimental Therapeutics321 (3): 1054-61. June 2007. PMID17337633. doi:10.1124/jpet.106.117507.
«Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior». Neuron53 (3): 439-52. February 2007. PMID17270739. doi:10.1016/j.neuron.2007.01.008.
«Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells». European Journal of Pharmacology594 (1-3): 32-8. October 2008. PMID18703043. doi:10.1016/j.ejphar.2008.07.040.
«OSIRIS: a tool for retrieving literature about sequence variants». Bioinformatics22 (20): 2567-9. October 2006. PMID16882651. doi:10.1093/bioinformatics/btl421. «Supplementary material to article».
«Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists». Journal of Medicinal Chemistry44 (6): 1003-10. March 2001. PMID11300881. doi:10.1021/jm000491y.
«Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene». Neuropsychobiology49 (1): 38-41. 2004. PMID14730199. doi:10.1159/000075337.
«Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group». Lancet347 (9011): 1294-6. May 1996. PMID8622505. doi:10.1016/s0140-6736(96)90939-3.
«Association study of two polymorphisms of the serotonin-2A receptor gene and suicide attempts». American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 147B (5): 645-9. July 2008. PMID18163387. doi:10.1002/ajmg.b.30642.
«HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies». Current Medicinal Chemistry14 (19): 2053-69. 2007. PMID17691947. doi:10.2174/092986707781368450.
«Genetic evaluation of the serotonergic system in chronic fatigue syndrome». Psychoneuroendocrinology33 (2): 188-97. February 2008. PMID18079067. doi:10.1016/j.psyneuen.2007.11.001.
«[11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography». Life Sciences58 (10): PL 187-92. 1996. PMID8602111. doi:10.1016/0024-3205(96)00013-6.
«Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography». Biological Psychiatry55 (3): 217-24. February 2004. PMID14744461. doi:10.1016/j.biopsych.2003.08.015.
«Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei». The International Journal of Neuropsychopharmacology8 (3): 391-401. September 2005. PMID15801987. doi:10.1017/S1461145705005055.
«Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome». The International Journal of Neuropsychopharmacology10 (2): 245-52. April 2007. PMID16945163. doi:10.1017/S1461145706006559.
«Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging». Psychiatry Research68 (1): 11-22. November 1996. PMID9027929. doi:10.1016/S0925-4927(96)02806-5.
«Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction». Brain Research813 (1): 167-71. November 1998. PMID9824691. doi:10.1016/S0006-8993(98)00909-3.
«A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables». NeuroImage21 (3): 1105-13. March 2004. PMID15006678. doi:10.1016/j.neuroimage.2003.10.046.
«Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder». Biological Psychiatry63 (6): 569-76. March 2008. PMID17884017. doi:10.1016/j.biopsych.2007.07.009.
